LIDDS

LIDDS is a Swedish pharmaceutical technology firm specializing in local drug delivery solutions for cancer treatment. The company creates solid depots that release medication over extended periods directly into tumors to minimize systemic side effects while maximizing therapeutic impact.

• Innovation: The NanoZolid platform enables controlled drug release lasting up to six months through a versatile suspension formulation.
• Industries: Operations focus primarily on oncology, targeting specific indication areas with high-dose local administration strategies.
• Customers: Business models involve licensing the proprietary technology to partners alongside developing an internal clinical pipeline.

The company is currently listed on the Nasdaq First North Growth market and maintains multiple projects in early to late-stage clinical development.